Overexpression of human epidermal growth factor receptor type 2 (HER2, also referred to as HER2/neu or ErbB-2), a 185-kD receptor first described more than two decades ago [4], occurs in 20 to 30% of invasive breast cancers. Here, ERBB2 is linked to invasive breast carcinoma.